Black Diamond Therapeutics (BDTX) Operating Leases (2020 - 2026)

Black Diamond Therapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $14.1 million for Q1 2026.

• Quarterly Operating Leases fell 21.22% year-over-year to $14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.1 million (down 21.22% YoY) and the FY2025 annual result came in at $15.1 million, down 19.77% from the prior year.
• Operating Leases was $14.1 million for Q1 2026 at Black Diamond Therapeutics, down from $15.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $28.8 million in Q2 2022 and bottomed at $14.1 million in Q1 2026.
• A 5-year average of $21.8 million and a median of $23.0 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases surged 115.65% — and 2025, when it tumbled 30.28%.
• Black Diamond Therapeutics' Operating Leases stood at $25.3 million in 2022, then fell by 12.31% to $22.2 million in 2023, then dropped by 15.34% to $18.8 million in 2024, then retreated by 19.77% to $15.1 million in 2025, then retreated by 6.5% to $14.1 million in 2026.
• Business Quant data shows BDTX's Operating Leases at $14.1 million in Q1 2026, $15.1 million in Q4 2025, and $16.0 million in Q3 2025.